

## AMENDMENTS TO THE CLAIMS

1-42. (Cancelled)

43. (Previously presented) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein  $R_7$  is  $NH_2$ .

44-49. (Cancelled)

50. (Previously presented) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein  $R_g$  is the amino acid side chain of Asn, D-4Hyp, or L-/D-Pro when said compound is a linear peptide, wherein, when  $R_g$  is the amino acid side chain of D-4Hyp or L-/D-Pro, the side chain is cyclized by attachment to the N atom bonded to the C atom to which  $R_g$  is attached.


51. (Previously presented) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein  $R_h$  is the amino acid side chain of Pro or D-Pro, wherein the side chain is cyclized by attachment to the N atom bonded to the C atom to which  $R_h$  is attached.

52. (Previously presented) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein  $R_i$  is the amino acid side chain of Tyr.

53. (Previously presented) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein  $R_j$  is the amino acid side chain of Asn.

54-162. (Cancelled).

163. (Previously presented) A compound having the formula:



or a retro form, an all D form, or a retro all D form thereof, said compound optionally being cyclic through a covalent bond between  $N^*$  and  $C^*$ ;

wherein:

$X$  is H, Ac, TFa, DBF, ASAL optionally iodinated, or HP;

$l$  and  $n$  are 1;

$p$  and  $q$  are independently 0 or 1;

$R_c$  is the side chain of Gly;

R<sub>d</sub> is the side chain of Ala;

R<sub>f</sub> is the acid side chain of Gly;

R<sub>g</sub> is the side chain of L-Hyp, D-Hyp, Pro, D-Pro, Ncg, A2C, Gly, Asn, T4c, or Pc, if the compound is a cyclic compound, or R<sub>g</sub> is the side chain of D-Hyp, Pro, D-Pro, Ncg, A2C, Gly, Asn, T4c, or Pc, if the compound is a linear peptide, wherein said side chain of L-Hyp, D-Hyp, Pro, D-Pro, or Thio-Pro is cyclized by attachment to the N atom bonded to the C atom to which R<sub>g</sub> is attached;

R<sub>h</sub> is the side chain of Pro, D-Pro, or Ala, wherein said side chain of Pro or D-Pro is cyclized by attachment to the N atom bonded to the C atom to which R<sub>h</sub> is attached;

R<sub>i</sub> is the side chain of Tyr or D-Tyr, wherein the aromatic ring of said side chain is optionally substituted with one or more halogen groups;

R<sub>j</sub> is the side chain of Gln or Asn;

R<sub>7</sub> is OH or NH<sub>2</sub>, or is absent if the compound is cyclized between N\* and C\*, or a pharmaceutically acceptable salt thereof.

164. (Cancelled)

165. (Previously presented) The compound of claim 163, wherein said compound is cyclo(-Gly-Ala-Gly-Hyp-Pro-Tyr-Asn-) (SEQ ID NO:287), or a pharmaceutically acceptable salt thereof.

166. (Previously presented) The compound of claim 163, wherein said compound is cyclo(-Tyr-Pro-4Hyp-Gly-Ala-Gly-Asn-) (SEQ ID NO:174), or a pharmaceutically acceptable salt thereof.

167. (Previously presented) The compound of claim 163, wherein said compound is cyclo(-Gly-Ala-Gly-Pro-Pro-Tyr-Asn-) (SEQ ID NO:288), or a pharmaceutically acceptable salt thereof.

168. (Currently amended) The compound of claim 163, wherein said compound is cyclo(-Gly-Ala-Gly-Pro-Pro-Tyr-Gln-) (SEQ ID NO:300 ~~NO:286~~), or a pharmaceutically acceptable salt thereof.

169. (Currently amended) The compound of claim 163, wherein said compound is Gly-Ala-Gly-Pro-Pro-Tyr-NH<sub>2</sub> (SEQ ID NO:301 ~~NO:267~~), or a pharmaceutically acceptable salt thereof.

170. (Currently amended) The compound of claim 163, wherein said compound is Ac-D-Tyr-D-Pro-D-Pro-Gly-D-Ala-Gly-NH<sub>2</sub> (~~SEQ ID NO:284~~), or a pharmaceutically acceptable salt thereof.

171. (Currently amended) The compound of claim 163, wherein said compound is Ac-D-Tyr-D-Hyp-D-Hyp-Gly-D-Ala-Gly-NH<sub>2</sub> (SEQ ID NO:245), or a pharmaceutically acceptable salt thereof.

172. (Previously presented) The compound of claim 163, wherein said compound is Gly-Ala-Gly-Asn-Tyr-NH<sub>2</sub> (SEQ ID NO:254), or a pharmaceutically acceptable salt thereof.

173-193. (Cancelled)

194. (Previously presented) The compound of claim 163, or a pharmaceutically acceptable salt thereof, wherein X is Ac or H and R<sub>g</sub> is selected from the group consisting of Pro, D-Pro, Hyp, D-Hyp, Gly, or Asn.

195-196. (Cancelled)